Franklin Genomic Advancements ETF (HELX)

Assets	$12.97M
Expense Ratio	0.50%
PE Ratio	33.90
Shares Out	450,000
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Ratio	n/a
1-Year Return	-2.71%

Volume	1,079
Open	28.80
Previous Close	28.86
Day's Range	28.80 - 29.39
52-Week Low	28.30
52-Week High	33.98
Beta	1.07
Holdings	66
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

43.05% of assets

Name	Symbol	Weight
Natera, Inc.	NTRA	5.80%
Vertex Pharmaceuticals Incorporated	VRTX	5.13%
Eli Lilly and Company	LLY	4.58%
Samsung Biologics Co.,Ltd.	207940	4.51%
Krystal Biotech, Inc.	KRYS	4.31%
Thermo Fisher Scientific Inc.	TMO	4.09%
Medpace Holdings, Inc.	MEDP	4.03%
Danaher Corporation	DHR	4.02%
Regeneron Pharmaceuticals, Inc.	REGN	3.95%
United Therapeutics Corporation	UTHR	2.63%